MedTrace Logo

A Post Marketing Surveillance As Required By Philippine Food And Drug Administration

NCT01781442 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2013-05-01

No results posted yet for this study

Summary

This is a post marketing surveillance which determines the safety profile of the product to Filipinos. This is a FDA requirement for registration.

Conditions

Interventions

DRUG

Temsirolimus

The recommended dose of Torisel is 25 mg infused over a 30-60 minute period once a week. Treatment will continue until disease progression or unacceptable toxicity. The use and dosage recommendations for Torisel will take place on the basis of the approved local product document and will be adjusted solely according to medical and therapeutic necessity.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2015-06-30
Completion
2015-06-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01781442 on ClinicalTrials.gov